• Orthocell Ltd (ASX: OCC) requests trading halt
• Pending announcement on proposed capital raising
• Trading halt to remain until earlier of announcement or market open on 17 October 2025

Orthocell Ltd (ASX: OCC) has requested a trading halt on its securities, pending the release of an announcement by the company in relation to a proposed capital raising. The trading halt will remain in place until the earlier of the company making an announcement about the proposed capital raising and the opening of trading on Friday, 17 October 2025. Orthocell is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. The company's portfolio includes collagen medical devices, nerve repair products, and autologous cell therapies for tendon and cartilage regeneration. Orthocell has received regulatory approvals for several of its products in various markets and is accelerating the development of its tendon cell therapy in the US.